CancerSafeScore

CancerSafeScore is a blood test that measures 10 tumor markers in women and 11 tumor markers in men. The test was developed by CancerSafe in Switzerland and France. The purpose of the test is to discover cancers early, when the cure rate is highest. 

Cancer is the second leading cause of death after cardiovascular disease. There are many different kinds of cancer, and each kind may produce molecules that enter the blood stream. Usually, the number of molecules is proportional to the size of the cancer, or tumor mass. This is why the molecules are referred to as tumor markers. 

Traditionally, a small number of tumor markers have been used to monitor response to treatment for an existing cancer. Over the past decade, many new markers have been discovered. In the US, only 4 of the markers in the CancerSafeScore panel are routinely measured. The other markers are being used at advanced cancer centers in the US or in cancer centers outside the US. CancerSafeScore combines all of these markers into a single test. 

By using a broad spectrum of markers, CancerSafeScore increases the likelihood of an accurate diagnosis. For example, breast cancer can cause elevations of three tumor markers, while lung cancer can cause elevations of five tumor markers. When we measure several markers for a specific cancer, the likelihood of early diagnosis is increased while the likelihood of a false positive reading is decreased. Each cancer has a pattern of markers associated with it. The pathologists who read the results base their interpretations on the tumor marker pattern. The pathologists have 20 years of experience with tumor markers, and are affiliated with the best known private cancer clinic in France. 

The following table shows the cancers that can be detected with CancerSafeScore, and the markers associated with each of the cancers: 

CancerSafeScore is obtained through a blood specimen drawn in the LifeScore laboratory. The blood is centrifuged and the serum separated from the red blood cells. The serum is frozen, and overnight mailed to the Chaperon-Tarbouriech Laboratory in Avignon, France. Results are transmitted to LifeScore within one to two days. The client receives an in-depth report that includes an interpretation of the results and information about the various markers. Should the results be abnormal, appropriate recommendations are provided. In effect, each test includes the equivalent of a consult with the CancerSafe physicians. 

The recommended age for obtaining the test is 50 or older, unless there are specific risk factors that may place an individual at risk earlier in their lives. Thereafter, it is recommended that the test be performed once each year. Over time, results are cumulatively reported with graphs, so that trends can easily be identified. 

For the first time, CancerSafeScore offers a comprehensive, convenient, affordable and non-invasive test for the early detection of 13 cancers. One in three people in America will develop cancer over the course of their lives. CancerSafeScore will increase the likelihood of finding the cancer as early as possible, when treatment will usually be the most effective.

Top of Page